ATE186462T1 - Gepirone enthaltende zusammensetzungen - Google Patents

Gepirone enthaltende zusammensetzungen

Info

Publication number
ATE186462T1
ATE186462T1 AT95113476T AT95113476T ATE186462T1 AT E186462 T1 ATE186462 T1 AT E186462T1 AT 95113476 T AT95113476 T AT 95113476T AT 95113476 T AT95113476 T AT 95113476T AT E186462 T1 ATE186462 T1 AT E186462T1
Authority
AT
Austria
Prior art keywords
gepirones
compositions containing
colourant
pref
hydroxypropylmethylcellulose
Prior art date
Application number
AT95113476T
Other languages
English (en)
Inventor
Stephen T David
Claude E Gallian
Joseph C H Chou
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE186462T1 publication Critical patent/ATE186462T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Electroluminescent Light Sources (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95113476T 1994-09-06 1995-08-28 Gepirone enthaltende zusammensetzungen ATE186462T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/301,281 US5478572A (en) 1994-09-06 1994-09-06 Gepirone dosage form

Publications (1)

Publication Number Publication Date
ATE186462T1 true ATE186462T1 (de) 1999-11-15

Family

ID=23162703

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95113476T ATE186462T1 (de) 1994-09-06 1995-08-28 Gepirone enthaltende zusammensetzungen

Country Status (25)

Country Link
US (1) US5478572A (de)
EP (1) EP0700680B1 (de)
JP (1) JP4540756B2 (de)
KR (1) KR100380806B1 (de)
CN (1) CN1096858C (de)
AT (1) ATE186462T1 (de)
AU (1) AU702282B2 (de)
CA (1) CA2157323C (de)
CY (1) CY2222B1 (de)
CZ (1) CZ286417B6 (de)
DE (1) DE69513254T2 (de)
DK (1) DK0700680T3 (de)
ES (1) ES2142432T3 (de)
FI (1) FI117319B (de)
GR (1) GR3032598T3 (de)
HK (1) HK1014666A1 (de)
HU (1) HU227339B1 (de)
IL (1) IL114984A (de)
NO (1) NO307814B1 (de)
NZ (1) NZ272855A (de)
PL (1) PL180691B1 (de)
RU (1) RU2155044C2 (de)
SG (1) SG30436A1 (de)
TW (1) TW445152B (de)
ZA (1) ZA957144B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
US20060068002A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
CN100367965C (zh) * 1999-12-20 2008-02-13 法布瑞－克雷默制药有限公司 吉吡隆代谢物在制备改善哺乳动物不良心理状态的组合物上的应用
KR20040018314A (ko) * 2000-12-08 2004-03-03 악조 노벨 엔.브이. 게피론을 함유하는 경구 투여용 연장 방출형 제제
AU2002236166B2 (en) 2001-05-01 2006-12-07 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030152621A1 (en) * 2001-11-21 2003-08-14 Egberink J. G. J. Pharmaceutical formulation of gepirone for oral administration
TW200306866A (en) * 2002-05-07 2003-12-01 Akzo Nobel Nv A method to improve surface properties of pharmaceutical tablets
EP1545469A1 (de) * 2002-09-24 2005-06-29 Akzo Nobel N.V. Methode zur verbesserung pharmazeutischer tabletten mit einer matrix aus celluloseether
PL196544B1 (pl) 2003-08-08 2008-01-31 Biovail Lab Int Srl Tabletka o zmodyfikowanym uwalnianiu
AR049478A1 (es) * 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
ATE481971T1 (de) * 2004-07-15 2010-10-15 Abbott Healthcare Products Bv Formulierung von 3-amino-8-(1-piperazinyl)-2h- 1benzopyran-2-on mit verzögerter freisetzung
US20060013874A1 (en) * 2004-07-15 2006-01-19 Solvay Pharmaceuticals B.V. Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one
AU2004324868B2 (en) * 2004-11-05 2010-04-29 Fabre Kramer Holdings Inc High-dosage extended-release formulation of gepirone
US20060099267A1 (en) * 2004-11-05 2006-05-11 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
JP2008542419A (ja) * 2005-06-09 2008-11-27 ユーロ−セルティーク エス．エイ． 神経刺激性ステロイドの医薬組成物及びその使用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4690824A (en) * 1983-07-07 1987-09-01 Redi-Rowell, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
SE8704097D0 (sv) * 1987-10-22 1987-10-22 Astra Ab Oral formulation of buspirone and salts thereof
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5124346A (en) * 1991-04-23 1992-06-23 Pfizer Inc. Synergistic combinations in the treatment of anxiety
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5292766A (en) * 1992-03-25 1994-03-08 Eli Lilly And Company Method for improving primary memory and/or learning
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
ES2142432T3 (es) 2000-04-16
HU227339B1 (en) 2011-04-28
GR3032598T3 (en) 2000-05-31
IL114984A (en) 1999-10-28
HU9502599D0 (en) 1995-11-28
NO307814B1 (no) 2000-06-05
EP0700680B1 (de) 1999-11-10
CZ286417B6 (en) 2000-04-12
CZ227595A3 (en) 1996-03-13
EP0700680A1 (de) 1996-03-13
IL114984A0 (en) 1995-12-08
FI954154A (fi) 1996-03-07
CA2157323C (en) 2004-01-20
JP4540756B2 (ja) 2010-09-08
HUT73182A (en) 1996-06-28
SG30436A1 (en) 1996-06-01
AU3043895A (en) 1996-03-21
AU702282B2 (en) 1999-02-18
DE69513254D1 (de) 1999-12-16
CN1128142A (zh) 1996-08-07
HK1014666A1 (en) 1999-09-30
RU2155044C2 (ru) 2000-08-27
DK0700680T3 (da) 2000-05-01
PL310298A1 (en) 1996-03-18
TW445152B (en) 2001-07-11
CY2222B1 (en) 2003-04-18
DE69513254T2 (de) 2000-06-15
FI954154A0 (fi) 1995-09-05
ZA957144B (en) 1996-03-26
FI117319B (fi) 2006-09-15
US5478572A (en) 1995-12-26
PL180691B1 (en) 2001-03-30
CN1096858C (zh) 2002-12-25
JPH08183736A (ja) 1996-07-16
KR960010007A (ko) 1996-04-20
CA2157323A1 (en) 1996-03-07
NO953212L (no) 1996-03-07
NZ272855A (en) 1997-05-26
NO953212D0 (no) 1995-08-16
KR100380806B1 (ko) 2003-07-10

Similar Documents

Publication Publication Date Title
ATE186462T1 (de) Gepirone enthaltende zusammensetzungen
NO20065390L (no) Farmasoytisk preparat i fast enhetsdoseringsform
NO20073429L (no) Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat
AR016827A1 (es) PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
HUT62467A (en) Process for producing locally applicable pharmaceutical compositions comprising allylamine derivative, against fungus infection of nails
DE69006365D1 (de) Unbeschichtete pharmazeutische reaktionstablette.
NO20004208D0 (no) Fornettet stivelse med høyt amyloseinnhold og med funksjonelle grupper som en matriks for frigivning av farmasøytiske midler
HUP0202461A2 (hu) Gyógyászati készítmények és azok agyvérzés, diabetes és/vagy elzáródásos szívbénulás megelőzésében történő alkalmazása
KR900005964A (ko) 분산성 제형
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
EA200001201A3 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
CA2047744A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
IS7208A (is) Snöggbráðnandi lyfjagjafarform til inntöku um munn
FI932552A0 (fi) Foerfarande foer framstaellning av en fast enhet doseringsform foer reglerad utloesningen
NO954952D0 (no) Fremgangsmåte for fremstilling av en oral fast-stoff doseringsform som inneholder diklofenac
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
NO992999L (no) Farmasöytisk blanding for oral administrering
KR930021206A (ko) 시타라빈 옥포스페이트 경질 캡슐제
KR940006585A (ko) 경구용 오메프라졸 약제의 코어 조성물을 제조하는 방법
BG103023A (en) Bronchodilatation medicamentous form
UA50814C2 (uk) Анальгетичний лікарський засіб
BRPI0315657B8 (pt) formulação de dosagem sólida, comprimido para liberação controlada, método de fabricar uma medicação de liberação controlada, composição farmacêutica e uso de uma composição

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification